A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units for transplantation in pediatric and adult patients with hematologic malignancies and other indications

In order for our site to display correctly you will need a newer version of your web browser.

Currently we test and support the following browsers:

FireFox version 3.0 and above (Windows and Mac)
Safari version 5.0 and above (Windows and Mac)
Internet Explorer version 7.0 and above (Windows)

Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.

Research

Stem Cell Bone Marrow Transplant

Supportive Stem Cell Bone Marrow Transplant Studies

Back to Current Clinical Trials

Non-Therapeutic Protocol

10-CBA: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units for transplantation in pediatric and adult patients with hematologic malignancies and other indications

Type of Protocol/Clinical Study

Associated Stem Cell Transplant Studies

Description

Patients enrolled in this access and distribution protocol may receive unlicensed Cord Blood units (CBU) for their transplantation.

Beginning October 2011, the FDA considers cord blood as a biological drug. Cord blood units (CBU) that were not collected, tested, or stored exactly according to FDA standards may be used for transplant if the transplant is done as part of a study. Most of the CBUs that are currently available in CB banks in the US and other countries were collected before the FDA set these new standards. Although these CBUs may not meet FDA standards, they meet similar standards set and followed by the National Marrow Donor Program (NMDP) for years.

Objectives

The primary objective of this study is to examine the incidence of neutrophil recovery after cord transplantation.

In participants receiving a non-licensed CBU:

To determine the frequency of graft rejection.
To determine the frequency of infection.
To determine the frequency of serious infusion reaction.
To determine the 1 year survival rate.

Eligibility

Only current St. Jude patients are eligible for non-therapeutic studies.
Participant is receiving an allogeneic hematopoietic stem cell transplant at St. Jude Children’s Research Hospital using an unlicensed cord blood unit (CBU).
The patient has a disorder affecting the hematopoietic system that is either inherited, acquired, or a result from myeloablative treatment.

Principal Investigator

Mari Dallas, MD

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.

Print Email This Article